MLPA probes hybridize to target regions of the BRCA1 or BRCA2 gene and are amplified by multiplex PCR. The amplification products are analyzed by capillary electrophoresis and copy numbers for these BRCA1 or BRCA2 target regions are generated.
This test is used to detect the presence of BRCA1 (OMIM:113705) or BRCA2 (OMIM: 600185) deletions and duplications. BRCA gene deletion and duplication analysis can be performed on patients with no BRCA mutations detected by sequence analysis but have a clinical presentation consistent with BRCA-related disorders or on relatives of a patient with a known BRCA deletion/duplication mutation.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This assay will not detect point mutations or frame-shift mutations in the BRCA1 or BRCA2 gene.
10 - 28 days (most tests signed out within 10 days after insurance authorization is received).
- Myriad BRACAnalysis Large Rearrangement Test (BART) Equivalent
- BRCA Tier 2
- BRCA1 Gene Deletion and Duplication Analysis
- BRCA1 Deletion
- BRCA1 Duplication
- BRCA2 Gene Deletion and Duplication Analysis
- BRCA2 Deletion
- BRCA2 Duplication
- Prostate Cancer
- Breast Cancer
- Pancreatic Cancer
- Ovarian Cancer
- BRCA Large Rearrangement Test (BART)
Please specify BRCA1 Deletion/Duplication (BRC1D), BRCA2 Deletion/Duplication (BRC2D), or both BRCA1 and BRCA2 Deletion/Duplication (BRC2). Collect specimen in a lavender top tube. Send intact specimen within 24 hours if stored at room temperature or within 5 days if stored refrigerated. Include the patient's family history, pedigree, and ethnicity on the test requisition. Obtaining informed consent from the patient prior to genetic testing is strongly recommended. If desired, a UMHS Request and Consent for Genetic Testing form can be obtained from the MMGL Molecular Genetics Laboratory by contacting the MLabs Client Services Center at 800-862-7284 or online at https://mlabs.umich.edu/sites/default/files/2020-01/file/pci-mmgl_infor….
Most insurance carriers require prior authorization for payment. BRCA testing will not begin until insurance prior authorization is received by the MMGL Laboratory or it has been confirmed that prior authorization is not required. It is the obligation of the ordering health care provider to obtain prior authorization before testing can begin. To obtain BCN prior authorization call Joint Venture Hospital Laboratories (JVHL) at 800-445-4979; for HAP refer to CareAffiliate via www.hap.org; for all others, contact the plan directly. By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician.Test includes medical geneticist interpretation of results billed as a separate additional charge. This test is not available without interpretation.